Third Rock Ventures Closes Fund V, at $770M

third rock venturesThird Rock Ventures, LLC, a Boston, MA-based life sciences venture capital firm, closed Third Rock Ventures V, LP, at $770m.

With Fund V, the firm will continue to execute on its strategy of discovering, launching and building innovative life sciences companies.

Since its inception in 2007, the firm has raised $2.7 billion to create companies focused in many different areas of high unmet medical need including:

  • cancer,
  • neurological disorders,
  • rare genetic diseases,
  • immune disorders, and
  • cardiovascular diseases.

Third Rock focuses on building product engine companies, which are built on biological insights and technology platforms, with the potential to generate multiple therapeutics. To date, the firm has invested in more than 50 companies, which have launched ten products, including five therapeutics, three diagnostics and two devices.

Fund V partners include:

  • Abbie Celniker, Ph.D.;
  • Neil Exter;
  • Kevin Gillis;
  • Reid Huber, Ph.D.;
  • Steve Kafka, Ph.D.;
  • Sarah Larson;
  • Christoph Lengauer, Ph.D.;
  • Craig Muir;
  • Cary Pfeffer, M.D.;
  • Robert Tepper, M.D.; and
  • Jeffrey Tong, Ph.D.




Join the discussion